Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study of its benmelstobart injection at the 2025 American Society of Clinical Oncology Annual Meeting, a Thursday Hong Kong bourse filing said.
The drug is being studied for use with or without anlotinib hydrochloride capsules as maintenance treatment for non-small cell lung cancer without progression following chemoradiotherapy.
The median progression-free survival of the arm of benmelstobart in combination with anlotinib was significantly prolonged with a 51% lower risk of disease progression or death, compared with the arm of the placebo.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。